Overview

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
It is a phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Huaota Biopharmaceutical Co., Ltd.